English | 中文

Hudson product information:



Hudson Cata#: HB0034

Product Name: BPR1J-097

CAS#: 179324-69-7

Chemical Formula: C19H25BN4O4

Exact Mass: 384.19689

Molecular Weight: 384.24

Purity: 99%

Storage Info: N/A

Synonym: PS-341. US brand name: VELCADE. Code names: LDP 341;MLN341.

 

Structure Formula:
Price:

Structure Formula Not Available.

10 mg / $70.00
25mg / $140.00

Product Info::

BPR1J-097 was discovered by a rational design strategy. BPR1J-097 with a novel sulphonamide pharmacophore exhibits potent FLT3-inhibitory activity and has potent growth-inhibitory effects on FLT3-ITD leukaemic cells. According to our SAR studies, It was found that sulphonamide pharmacophore preferred at meta-position of the phenyl ring, and that replacement the sulphonamide group of BPR1J-097 with the urea group resulted in a significant loss in cellular potency. Inhibition of FLT3 resulted in blockage of FLT3 and STAT5 phosphorylation and triggered apoptosis in cancer cells relying on FLT3 signalling for survival. In addition, BPR1J-097 showed favourable pharmacokinetic properties and significant dose dependent tumour reduction in FLT3-ITD murine xenograft models. These results demonstrate the potential of BPR1J-097 as a therapeutic candidate for treatment of AML patients. Further preclinical and clinical studies in AML patients are warranted. (source: Br J Cancer. 2012 Jan 31;106(3):475-81. doi: 10.1038/bjc.2011.564. Epub 2011 Dec 20.).

If you want to make an order, please contact 1 (732) 640-2533

or email wzhuang@hudsonbiopharma.com

 

References (Review papers):

1: Lin WH, Jiaang WT, Chen CW, Yen KJ, Hsieh SY, Yen SC, Chen CP, Chang KY, Chang CY, Chang TY, Huang YL, Yeh TK, Chao YS, Chen CT, Hsu JT. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br J Cancer. 2012 Jan 31;106(3):475-81. doi: 10.1038/bjc.2011.564. Epub 2011 Dec 20. PubMed PMID: 22187040; PubMed Central PMCID: PMC3273346.